New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
08:37 EDTTLOGTetraLogic announces selection of Phase 2 dose for birinapant, azacitidine study
TetraLogic announced that, based upon data from its Phase 1b study of birinapant in combination with azacitidine in patients with relapsed/refractory or na´ve higher risk MDS, it selected a dose of 13mg/m2 twice weekly for three weeks out of four to be used in its Phase 2 clinical trial. The primary objective of the Phase 1b clinical study is to characterize the safety and tolerability and determine the recommended phase 2 dose of birinapant when administered in combination with azacitidine. Additional objectives of the study are to assess any preliminary indications of efficacy and pharmacodynamics of the combination.
News For TLOG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
10:14 EDTTLOGTetraLogic management to meet with Guggenheim
Meetings to be held in New York/San Fransicso on November 18 hosted by Guggenheim.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use